(Q37464688)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

review article

1 reference

title

The global portfolio of new antimalarial medicines under development (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

author name string

P Olliaro

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

language of work or name

English

0 references

publication date

29 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

Clinical Pharmacology & Therapeutics

27 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

page(s)

584-595

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

Combating malaria in Africa

27 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

The effect of combinations of qinghaosu (artemisinin) with standard antimalarial drugs in the suppressive treatment of malaria in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Effects of artesunate-mefloquine combination on incidence of Plasmodium falciparum malaria and mefloquine resistance in western Thailand: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Artesunate combinations for treatment of malaria: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Strategies for the prevention of antimalarial drug resistance: rationale for combination chemotherapy for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Artemisone--a highly active antimalarial drug of the artemisinin class

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Evidence of Artemisinin-Resistant Malaria in Western Cambodia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Identification of an antimalarial synthetic trioxolane drug development candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Ensuring sustained ACT production and reliable artemisinin supply

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Selection of a trioxaquine as an antimalarial drug candidate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Fosmidomycin for the treatment of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Synthesis and structure-activity relationships of 4-pyridones as potential antimalarials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Randomized dose-ranging study of the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of Plasmodium vivax malaria in Thailand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Genome sequence of the human malaria parasite Plasmodium falciparum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Comparative genomics of the neglected human malaria parasite Plasmodium vivax

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Genomic-scale prioritization of drug targets: the TDR Targets database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Neglected disease research and development: how much are we really spending?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Malaria. Did they really say ... eradication?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Editorial commentary: mortality associated with severe Plasmodium falciparum malaria increases with age.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Comparative pharmacokinetics of intramuscular artesunate and artemether in patients with severe falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

A class of potent antimalarials and their specific accumulation in infected erythrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Virtual drug discovery and development for neglected diseases through public-private partnerships

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

Financing R&D for neglected diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FCLPT.2009.51

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/CLPT.2009.51

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19404247%20AND%20SRC:MED&resulttype=core&format=json

27 January 2020

1 reference